MediPharm Labs Corp. MEDIF announced first-quarter financial results Friday.
The global extraction, distillation, purification and cannabinoid isolation company generated revenue of $22 million, a 115-percent increase from the fourth quarter of 2018.
MediPharm posted a $6.9-million gross profit with a 31-percent gross margin. The company's adjusted EBITDA of $4.3 million marked a 102-percent increase over the fourth quarter of 2018 and a 20-percent margin. The company reported a net loss of $573,000 for the quarter.
Other highlights that were mentioned include the acquisition of more than 5 million grams of dried cannabis during the last two weeks of the quarter.
The quarterly print sets the pace for "continued robust growth," MediPharm CEO Patrick McCutcheon said in a statement.
“Our revenue and adjusted EBITDA performance ... illustrates the value of our specialized focus and ability to execute as the Canadian market's leading extraction experts and providers of high-quality cannabinoid-based derivative formulations at scale."
MediPharm's next steps include advancing efforts around distillate; white label solutions; topicals; and vaporized items, the CEO said.
“Our white label offering will be an enduring advantage and attractive solution for LP’s, direct-to-consumer brands and CPG companies, which we expect will also accelerate our growth in the months and years ahead.”
Related Links:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.